The burgeoning landscape of medication for excess body fat and type 2 metabolic disorder is currently witnessing considerable excitement surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 receptor agonists, significant distinctions in their pharmacological profiles and clinical study results are emerging.… Read More

Arriving in the arena of excess body fat management, retatrutide presents a unique approach. Unlike many available medications, retatrutide works as a twin agonist, simultaneously targeting both GLP peptide-1 (GLP-1) and glucose-dependent insulinotropic substance (GIP) binding sites. This concurrent engagement promotes various advantageous effec… Read More